The Effects of Obesity on Anti-Cancer Immunity and Cancer Immunotherapy.
T-cell exhaustion
cancer
checkpoint therapy
immunotherapy
inflammation
metabolic syndrome
obesity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
14 May 2020
14 May 2020
Historique:
received:
02
04
2020
revised:
29
04
2020
accepted:
12
05
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
20
5
2020
Statut:
epublish
Résumé
Cancer is one of the leading causes of morbidity and mortality worldwide. Traditional treatments include surgery, chemotherapy and radiation therapy, and more recently targeted therapies including immunotherapy are becoming routine care for some cancers. Immunotherapy aims to upregulate the patient's own immune system, enabling it to destroy cancerous cells. Obesity is a metabolic disorder characterized by significant weight that is an important contributor to many different diseases, including cancers. Obesity impacts the immune system and causes, among other things, a state of chronic low-grade inflammation. This is hypothesized to impact the efficacy of the immunotherapies. This review discusses the effects of obesity on the immune system and cancer immunotherapy, including the current evidence on the effect of obesity on immune checkpoint blockade, something which currently published reviews on this topic have not delved into. Data from several studies show that even though obesity causes a state of chronic low-grade inflammation with reductions in effector immune populations, it has a beneficial effect on patient survival following anti-PD-1/PD-L1 and anti-CTLA-4 treatment. However, research in this field is just emerging and further work is needed to expand our understanding of which cancer patients are likely to benefit from immunotherapy.
Identifiants
pubmed: 32422865
pii: cancers12051230
doi: 10.3390/cancers12051230
pmc: PMC7281442
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Immunother Cancer. 2019 Feb 27;7(1):57
pubmed: 30813970
J Immunother Cancer. 2016 Oct 18;4:59
pubmed: 27777769
Pathol Oncol Res. 2019 Jul;25(3):1233-1243
pubmed: 30759303
Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E10-5
pubmed: 12618361
Nat Immunol. 2012 Jul 19;13(8):707-12
pubmed: 22814340
Semin Immunol. 2012 Oct;24(5):321-30
pubmed: 22546243
J Exp Med. 1998 Jul 6;188(1):205-10
pubmed: 9653097
Lancet Oncol. 2018 Mar;19(3):310-322
pubmed: 29449192
FASEB J. 2004 Dec;18(15):1925-7
pubmed: 15469964
Indian J Endocrinol Metab. 2018 Nov-Dec;22(6):751-756
pubmed: 30766812
Oncogene. 2012 Sep 13;31(37):4117-27
pubmed: 22158049
Ann Clin Biochem. 2016 Nov;53(6):663-668
pubmed: 26787627
Expert Rev Clin Immunol. 2017 Oct;13(10):1001-1015
pubmed: 28795649
Nat Immunol. 2011 Jun;12(6):492-9
pubmed: 21739672
Immunity. 2007 Jun;26(6):726-40
pubmed: 17582345
EBioMedicine. 2018 Apr;30:237-247
pubmed: 29548899
JAMA. 2019 Apr 2;321(13):1247-1248
pubmed: 30882850
Future Lipidol. 2008;3(5):545-556
pubmed: 18978945
Pediatr Gastroenterol Hepatol Nutr. 2013 Sep;16(3):143-52
pubmed: 24224147
Adv Nutr. 2016 Jan 15;7(1):66-75
pubmed: 26773015
Cancer Med. 2019 Jan;8(1):80-93
pubmed: 30600646
Ann N Y Acad Sci. 2012 Oct;1271:37-43
pubmed: 23050962
Nat Rev Endocrinol. 2019 Mar;15(3):139-154
pubmed: 30459447
Gynecol Oncol. 2015 Jul;138(1):201-6
pubmed: 25870918
J Immunother Cancer. 2019 Mar 29;7(1):89
pubmed: 30922394
J Clin Invest. 2007 Jan;117(1):175-84
pubmed: 17200717
Sci Rep. 2017 Feb 17;7:42913
pubmed: 28211499
Mol Cell Endocrinol. 2010 Mar 25;316(2):104-8
pubmed: 19628019
PLoS One. 2018 Oct 1;13(10):e0204729
pubmed: 30273398
Curr Opin Immunol. 2018 Apr;51:181-186
pubmed: 29655021
Immunotherapy. 2018 Feb;10(2):149-160
pubmed: 29260623
Nature. 2003 Feb 20;421(6925):856-9
pubmed: 12594516
Am J Clin Oncol. 2016 Feb;39(1):98-106
pubmed: 26558876
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
JAMA Oncol. 2019 Dec 26;:
pubmed: 31876896
Cancer Manag Res. 2018 May 30;10:1365-1375
pubmed: 29881307
Front Oncol. 2019 Jul 18;9:596
pubmed: 31380268
Front Pharmacol. 2018 Jun 26;9:642
pubmed: 29997500
Eur Rev Med Pharmacol Sci. 2016 Apr;20(7):1300-6
pubmed: 27097950
Crit Rev Clin Lab Sci. 2009;46(4):167-89
pubmed: 19650714
Nat Rev Mol Cell Biol. 2008 May;9(5):367-77
pubmed: 18401346
Front Immunol. 2017 Aug 02;8:909
pubmed: 28824635
J Immunother Cancer. 2019 Aug 19;7(1):222
pubmed: 31426863
Nat Neurosci. 2005 May;8(5):566-70
pubmed: 15856064
Circulation. 2004 Sep 21;110(12):1564-71
pubmed: 15364812
J Exp Med. 2014 Nov 17;211(12):2373-83
pubmed: 25366964
Nat Rev Immunol. 2005 Aug;5(8):617-28
pubmed: 16056255
Diabetologia. 2006 Sep;49(9):2162-73
pubmed: 16865359
J Immunol. 2018 Oct 1;201(7):1837-1841
pubmed: 30135180
Immunology. 2010 Apr;129(4):474-81
pubmed: 20201977
J Obes. 2013;2013:291546
pubmed: 24073332
Diabetes Obes Metab. 2013 Sep;15 Suppl 3:34-8
pubmed: 24003919
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
J Immunol. 2014 May 15;192(10):4876-86
pubmed: 24711622
Cancers (Basel). 2019 Aug 19;11(8):
pubmed: 31430935
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
JAMA Oncol. 2016 Sep 1;2(9):1137-45
pubmed: 27196302
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Maturitas. 2017 Nov;105:8-15
pubmed: 28477990
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
Nat Med. 2019 Jan;25(1):141-151
pubmed: 30420753
Prz Menopauzalny. 2014 May;13(2):96-100
pubmed: 26327837
BMJ. 2007 Dec 1;335(7630):1134
pubmed: 17986716
Nature. 2009 Jul 9;460(7252):259-63
pubmed: 19516257
Immunology. 2018 Apr 27;:
pubmed: 29700809
Metabolism. 2007 Jul;56(7):998-1004
pubmed: 17570264
Nat Immunol. 2000 Oct;1(4):311-6
pubmed: 11017102
P T. 2017 Aug;42(8):514-521
pubmed: 28781505
Clin Cancer Res. 2015 Feb 15;21(4):687-92
pubmed: 25501578
Indian J Med Res. 2014 Sep;140(3):361-9
pubmed: 25366203
Immunol Rev. 2017 Mar;276(1):97-111
pubmed: 28258697
Blood. 2009 Oct 29;114(18):3803-12
pubmed: 19721009
Oncologist. 2010;15(6):556-65
pubmed: 20507889
Mol Cancer. 2019 Jan 15;18(1):10
pubmed: 30646912
Trends Endocrinol Metab. 2015 Feb;26(2):91-100
pubmed: 25573740
Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7265-70
pubmed: 12756299